Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Doxycycline Mono 100Mg Tab 50 By Lannett Pharma

NDC 00527-1338-50 UPC/GTIN No.3-05271-33850-1 Mfg.Part No.133850BRAND: DOXYCYCLINE NDC: 00527-1338-50,527133850 UPC: 3-05271-33850-1,305271338501 Lannett Co IncOnly Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Rx Item-Doxycycline Mono 100Mg Tab 50 By Lannett Pharma

$211.55$29.70

Item No.:RX400438 NDC No.527133850 UPC No.:305271338501 NDC No.00527-1338-50 UPC/GTIN No.3-05271-33850-1 MPN 133850 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,ResearchCo.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX Item. Rx Item No.Rx400438 Doxycycline 100mg Tab 50 by Lannett Pharma Item No.3400438 NDC No.00527133850 UPC No.305271338501 Other Name Adoxa,Monodox,Doxy

Have a question?

Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page of 14
To reduce the development of drug-resistant
bacteria and maintain the effectiveness of Monodox and other antibacterial drugs,
Monodox should be used only to treat or prevent infections th
at are proven or strongly susp
ected to be caused by bacteria.
DESCRIPTION
Doxycycline is broad-spectrum antibiotic synthetically derived from oxytetracycline. Monodox 100 mg, 75 mg, and 50 mg
capsules contain doxycycline monohydrate equi
valent to 100 mg, 75 mg, or 50 mg of
doxycycline for oral administration. The
chemical designation of the light-yellow crystallin
e powder is alpha-6-deoxy-5-oxytetracycline.
Structural formula:
C
22
H
24
N
2
O
8
H
2
O M.W. 462.45
Doxycycline has high degree of lipid solubility and low affinity for calcium binding. It is highly stable in normal human
serum. Doxycycline will not degrade into an epianhydro form.
Inert ingredients: colloidal silicon dioxide; magnesium stearate;
microcrystalline cellulose; sodium starch glycolate; and ha
rd
gelatin capsule which contains black iron oxide, red iron oxide, titanium dioxide, and yellow iron oxide for the 100 mg and 75
mg strengths, titanium dioxide and yellow iron oxide for the 50 mg
strength. The capsules are printed with edible ink containin
g
black iron oxide, red iron oxide, and yellow iron oxide for the 50 mg and 100 mg strengths and black iron oxide, FD&C Blue
No. 2, FD&C Red No. 40, FD&C Blue No. 1, and D&C Yellow No. 10 for the 75 mg strength.
CLINICAL PHARMACOLOGY
Tetracyclines are readily absorbed and are bo
und to plasma proteins in varying degrees
. They are concentrated by the liver in
the bile and excreted in the urine and f
eces at high concentrations in biologica
lly active form. Doxycycline is virtually
completely absorbed after oral administration.
Following 200 mg dose of doxycycline monohydrate, 24 normal
adult volunteers averaged the
following serum concentration
values: Time (hr): 0.5 1.0 1.5 2.0 3.0 4.0 8.0 12.0 24.0 48.0 72.0 Conc. 1.02 2.26 2.67 3.01 3.16 3.03 2.03 1.62 0.95 0.37 0.15 (
?
g/mL)
Average Observed Values Maximum Concentration 3.61
?
g/mL (? 0.9 sd) Time of Maximum Concentration 2.60 hr (? 1.10 sd) Elimination Rate Constant 0.049 per hr (? 0.030 sd) Half-Life 16.33 hr (? 4.53 sd)
Excretion of doxycycline by the kidney is
about 40%/72 hours in individuals with
normal function (creatinine clearance about
75 mL/min). This percentage excretion may fall as low as 1-
5%/72 hours in individuals with
severe renal insufficiency
(creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range
18-22 hours) in individuals with normal and severely impaired renal function.
Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page of 14
Hemodialysis does not alter serum half-life.
Microbiology:
The tetracyclines are primaril
y bacteriostatic and are thought to exert th
eir antimicrobial effect by the inhibition
of protein synthesis. The tetracyclines, including doxycycline, have similar antimicrobial spectrum of activity against wid
e
range of gram-positive and gram-negative microorganisms. Cros
s-resistance of these microorganisms to tetracyclines is
common.
Doxycycline has been shown to be active against most strains of the following microorganisms, both
in vitro
and in clinical
infections as described in the
INDICATIONS AND USAGE
section.
Aerobic Gram-Positive Microorganisms:
Because many strains of the following
groups of gram-positive microorganisms ha
ve been shown to be resistant to
tetracyclines, culture and susceptibility testing are recommended.
Bacillus anthracis
Listeria monocytogenes
Staphylococcus aureus*
*Doxycycline is not the dr
ug of choice in the treatment of an
y type of staphylococcal infection.
Up to 44 percent of strains of
Streptococcus pyogenes
and 74 percent of
Streptococcus faecalis
have been found to be resistant
to tetracycline drugs. Therefore,
tetracyclines should not be used to treat stre
ptococcal infections unl
ess the microorganism h
as
been demonstrated
to be susceptible.
Streptococcus pneumoniae
Aerobic Gram-Negative Microorganisms:
Bartonella bacilliformis
Haemophilus ducreyi
Brucella species
Haemophilus influenzae
Calymmatobacterium granulomatis
Neisseria gonorrhoeae
Campylobacter fetus
Vibrio cholerae
Francisella tularensis
Yersinia pestis
Because many strains of the following gr
oups of gram-negative micr
oorganisms have been shown to be resistant to
tetracyclines, culture and susceptibility testing are recommended:
Acinetobacter species
Klebsiella species
Enterobacter aerogenes
Shigella species
Escherichia coli
Anaerobic Microorganisms:
Actinomyces israelii
Fusobacterium fusiforme
Clostridium species
Other Microorganisms:
Borrelia recurrentis
Rickettsiae
Chlamydia psittaci
Treponema pallidum
Chlamydia trachomatis
Treponema pertenue
Mycoplasma pneumoniae
Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page of 14
Susceptibility Tests:
Dilution Techniques:
Quantitative methods are used to determine antimicrobial minimu
m inhibitory concentrations (MIC?s). These MIC?s provide
estimates of the susceptibility of bacteria to antimicrobial com
pounds. The MIC?s should be determined using standardized
procedure. Standardized procedures are based on dilution method
1,3
(broth or agar) or equivalent with standardized inoculum
concentrations and standardized concentra
tions of tetracycline powder. The MIC values
should be interpreted according to the
following criteria: Interpretive criteria for
Enterobacteriaceae
,
Staphylococcus aureus
and
Acinetobacter
spp. Microorganism
MIC Interpretive Standard (
?
g/mL) Susceptible (S)
Intermediate (I) Resistant (R)
Enterobacteriaceae
?


?
16
Staphylococcus
aureus
Acinetobacter
spp
.
Microorganisms that are susceptible to tetracyc
line are generally suscep
tible to doxycycline. Interpretive Criteria for
Haemophilus
spp. Microorganism MIC Interpretive Standard (
?
g/mL) Susceptible (S) Intermediate (I) Resistant (R)
Haemophilus
spp.
?


?

Interpretive criteria for
Haemophilus
spp. are applicable only to tests performed by broth microdilution method using
Haemophilus
Test Medium (HTM).
1,3
Microorganisms that are susceptible to tetracyc
line are generally suscep
tible to doxycycline.
Interpretive Criteria for
Neisseria gonorrhoeae
Microorganism MIC Interpretive Standard (
?
g/mL) Susceptible (S) Intermediate (I) Resistant (R)
Neisseria
gonorrhoeae
?
0.25 0.5 1
?

Interpretive criteria for
Neisseria gonorrhoeae
are applicable only to tests performed by agar dilution method using GC agar
base with 1% defined growth supplement.
1,3
Microorganisms that are susceptible to tetracyc
line are generally suscep
tible to doxycycline. Interpretive Criteria for
Streptococcus pneumoniae
Microorganism MIC Interpretive Standard (
?
g/mL) Susceptible (S) Intermediate (I) Resistant (R)
Streptococcus
p
neumoniae
?


?

Interpretive criteria for
Streptococcus pneumoniae
are applicable only to tests performed by broth microdilution method using
Cation-Adjusted Mueller-Hinton broth with 2.5% 5% lysed horse blood.
1,3
Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page of 14
Microoganisms that are suscepti
ble to tetracycline are generally susceptible to doxycycline. Interpretive Criteria for
Bacillus anthracis
and
Brucella
spp. Microorganism MIC Interpretive Standard (
?
g/mL) Susceptible (S) Intermediate (I) Resistant (R)
Bacillus anthracis
?



Brucella
spp.
Broth Microdilution performed in unsupplemented
Brucella
broth pH adjusted to 7.1 0.1 for
Brucella
spp.
5
For some organism/antimicrobial agent combinations, the absence or rare occurrence of resistant strains precludes defining
results for categories other than ?susceptible.? For strains
yielding results suggestive of
?nonsusceptible? category, organ
ism
identification and antimicrobial susceptib
ility test results should be confirmed.
5
Incubation in 5% CO
2
may be required for growth of some strains of
Brucella
spp. especially
B. abortus
.
Incubation broth MIC tests in CO
2
may decrease the MIC of tetracyclines, usually by one doubling dilution.
5
Microorganisms that are susceptible to tetracyc
line are generally suscep
tible to doxycycline. Interpretive Criteria for
Burkholderia mallei, Burkholderia pseudomallei
and
Yersinia
pestis
Microorganism MIC Interpretive Standard (
?
g/mL) Susceptible (S) Intermediate (I) Resistant (R)
Burkholderia mallei
?


?
16 Burkholderia
p
seudomallei
Yersinia pestis
Microorganisms that are susceptible to tetracyc
line are generally suscep
tible to doxycycline. Interpretive Criteria for
Franciscella tularensis
Microorganism MIC Interpretive Standard (
?
g/mL) Susceptible (S) Intermediate (I) Resistant (R)
Franciscella
tularensis
?



Broth Microdilutions performed in Cation-Adjusted Mueller-Hinton broth with 2% defined growth supplement for
Franciscella tularensis
5
For some organism/antimicrobial agent combinations, the absence or rare occurrence of resistant strains precludes defining
results for categories other than ?susceptible.? For strains
yielding results suggestive of
?nonsusceptible? category, organ
ism
identification and antimicrobial susceptib
ility test results should be confirmed.
5
Microorganisms that are susceptible to tetracyc
line are generally suscep
tible to doxycycline.
A report of ?Susceptible? indicates that the
pathogen is likely to be inhibited if the antimicrobial compound in the blood reac
hes
the concentrations usually achievable. report of ?Intermediate?
indicates that the result should be considered equivocal, and
,
if the microorganism is not fully susceptible to alternative, c
linically feasible drugs, the test should be repeated. This cate
gory
implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where hig
h
dosage of drug can be used. This category also provides buffer zone which prevents small uncontrolled technical factors from
causing major discrepancies in interpretation. report of ?Resis
tant? indicates that the pathogen is not likely to be inhibite
d if
the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Standardized susceptibility test procedures require the use of la
boratory control microorganisms to control the technical aspec
ts
Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page of 14
of the laboratory procedures. Standard tetracycline powder should provide the following MIC values:
Quality Control Ranges for MIC Broth Dilution Method
Microorganism ATCC Number Cation-Adjusted
Mueller-Hinton
(CAMHB)
MIC (
?
g/mL)
Escherichia coli
25922 0.5 2
Haemophilus influenzae 49247 4 32
a
Neisseria gonorrhoeae 49226 0.25 1
b
Pseudomonas aeruginosa
27853
8 32
Staphylococcus aureus
29213 0.12 1
Streptococcus pneumoniae
49619
0.06 0.5
c
a Range applicable only to tests performed by broth microdilution method using
Haemophilus
Test Medium (HTM).
1,3
b Range applicable only to tests performed by agar dilution method using GC agar base with 1% defined growth supplement.
1,3
c Range applicable only to tests performed by broth microdilution method using Cation-Adjusted Mueller-Hinton broth with
2.5% to 5% lysed horse blood.
1,3
Diffusion Techniques:
Quantitative methods that require measurement of zone diameters
also provide reproducible estimates of the susceptibility of
bacteria to antimicrobial compounds
. One such standardized procedure
2,3
requires the use of standardized inoculum
concentrations. This procedure uses paper disks impregnated with 30-
?
g tetracycline or 30-
?
g doxycycline to test the
susceptibility of microorganisms to doxycycline.
Reports from the laboratory providing results of th
e standard single-disk susceptibility test with 30-
?
g tetracycline-class disk
or the 30-
?
g doxycycline disk should be interpreted according to the following criteria: Interpretive Zone Diameters for
Staphylococcus aureus
Antimicrobial Agent
Zone Diameter (nearest whole mm) Susceptible (S) Intermediate (I) Resistant (R) Tetracycline
?
19 15 18
?
14
Doxycycline
?
16
13 15
?
12 Interpretive Zone Diameters for
Enterobacteriaceae
.
Antimicrobial Agent
Zone Diameter (nearest whole mm) Susceptible (S) Intermediate (I) Resistant (R) Tetracycline
?
15 12 14
?
11
Doxycycline
?
14
11 13
?
10 Minocycline
?
16 13 15
?
12 Interpretive Zone Diameters for
Acinetobactor
spp.
Antimicrobial Agent
Zone Diameter (nearest whole mm) Susceptible (S) Intermediate (I) Resistant (R) Tetracycline
?
15 12 14
?
11
Doxycycline
?
13
10 12
?

Minocycline
?
16 13 15
?
12
Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page 11 of 14
Pregnancy Category D:
There are no adequate and well-controlled studies on the use of
doxycycline in pregnant short-term, first trimester exposure.
There are no human data available to asse
ss the effects of long-term th
erapy of doxycyclin
e in pregnant women such as that
proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during
pregnancy by TERIS the Teratogen Information System concluded that therapeutic doses during pregnancy are unlikely to
pose substantial teratogenic risk (the quantity and quality of
data were assessed as limited to fair), but the data are insuf
ficient
to state that there is no risk.
6
A case-control study (18,515 mothers of infants with congenital
anomalies and 32,804 mothers of infants with no congenital
anomalies) shows weak but marginally statistically significan
t association with total malformations and use of doxycycline
anytime during pregnancy. (Sixty-three [0.19%] of the controls
and 56 [0.30%] of the cases we
re treated with doxycycline.)
This association was not seen when the analysis was confined to
maternal treatment during the period of organogenesis (i.e., in
the second and third months of gestation) with the exception of marginal relationship with neural tube defect based on only
two exposed cases.
7
A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early
first trimester. All mothers reported their ex
posed infants were normal at year of age.
8
Labor and Delivery:
The effect of tetracyclines on
labor and delivery is unknown.
Nursing Mothers:
Tetracyclines are excreted in human milk, however, the extent
of absorption of tetracyclines
, including doxycycline, by the
breastfed infant is not known. Short-term use by lactating wo
men is not necessarily contrain
dicated; however, the effects of
prolonged exposure to doxycycline in breast milk are unknown.
9
Because of the potential for adverse reactions in nursing
infants from doxycycline, decision should be made whether to discontinue nursing or to discontinue the drug, taking into
account the importance of the
drug to the mother. (See
WARNINGS
.)
Pediatric Use:
See
WARNINGS
and
DOSAGE AND ADMINISTRATION
sections.
ADVERSE REACTIONS
Due to oral doxycycline?s virtually complete absorption, side e
ffects to the lower bowel, particularly diarrhea, have been
infrequent. The following adverse reactions have b
een observed in patients receiving tetracyclines.
Gastrointestinal:
Anorexia, nausea, vomiting, diarrhea, glossitis, dysp
hagia, enterocolitis, and inflammatory lesions (with
monilial overgrowth) in the anogenital region. Hepatotoxicity has
been reported. These
reactions have been
caused by both the
oral and parenteral administration of tetracyclines. Rare instan
ces of esophagitis and esophageal ulcerations have been reporte
d
in patients receiving capsule and tablet forms of drugs in th
e tetracycline class. Most of these patients took medications
immediately before going to bed. (See
DOSAGE AND ADMINISTRATION
.)
Skin:
Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema
multiforme have been reported. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above.
(See
WARNINGS
.)
Renal Toxicity:
Rise in BUN has been reported and is apparently dose related. (See
WARNINGS
.)
Hypersensitivity Reactions:
Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness,
pericarditis, and exacerbation of sy
stemic lupus erythematosus.
Blood:
Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported with tetracyclines.
Other:
Bulging fontanels in infants and intr
acranial hypertension in adults. (See
PRECAUTIONS-General
.)
Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page 12 of 14
When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the
thyroid gland. No abnormalities of thyroid function are known to occur.
OVERDOSAGE
In case of overdosage, discontinue medication, treat symptomati
cally and institute supportive meas
ures. Dialysis does not alter
serum half-life, and it would not be of benefit in treating cases of overdosage.
DOSAGE AND ADMINISTRATION
THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF
THE OTHER TETRACYCLINES. EXCEEDING THE RECOMME
NDED DOSAGE MAY RESULT IN AN INCREASED
INCIDENCE OF SIDE EFFECTS.
Adults:
The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours or 50
mg every hours) followed by maintenance dose of 100 mg/day
. The maintenance dose may be administered as single dose
or as 50 mg every 12 hours. In the management of more severe
infections (particularly chronic
infections of the urinary tract),
100 mg every 12 hours is recommended.
For pediatric patients ab
ove eight years of age:
The recommended dosage schedule for pediatric patients weighing 100
pounds or less is mg/lb of body weight divided into two doses on the first day of treatment, followed by mg/lb of body
weight given as single daily dose or divided into two doses, on subsequent days. For more severe infections up to mg/lb of
body weight may be used. For pediatric patients ove
r 100 pounds the usual adult dose should be used.
Uncomplicated gonococcal infections in adul
ts (except anorectal infections in men):
100 mg, by mouth, twice day for
days. As an alternate single visit dose, administer 300 mg stat followed in one hour by second 300 mg dose.
Acute epididymo-orchitis caused by
N. gonorrhoeae:
100 mg, by mouth, twice day for at least 10 days.
Primary and secondary syphilis:
300 mg day in divided doses for at least 10 days.
Uncomplicated urethral, endocervical, or
rectal infection in adults caused by
Chlamydia trachomatis:
100 mg, by mouth,
twice day for at least days.
Nongonococcal urethritis caused by
C. trachomatis
and
U. urealyticum:
100 mg, by mouth, twice day for at least days.
Acute epididymo-orchitis caused by
C. trachomatis:
100 mg, by mouth, twice day for at least 10 days.
Inhalational anthrax (post-exposure):
ADULTS: 100 mg of doxycycline, by mouth, twice day for 60 days. CHILDREN:
weighing less than 100 pounds (45 kg); mg/lb (2.2 mg/kg) of body weight, by mouth, twice day for 60 days. Children
weighing 100 pounds or more
should receive
the adult dose.
When used in streptococcal infections, th
erapy should be continued for 10 days.
Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is
recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See
ADVERSE
REACTIONS
.) If gastric irritation occurs, doxycycline may be given with food. Ingestion of high fat meal has been shown to
delay the time to peak plasma concentrations by an average of one hour and 20 minutes. However, in the same study, food
enhanced the average peak concentration by 7.5% and the area under the curve by 5.7%.
HOW SUPPLIED
MONODOX
?
50 mg Capsules have white opaque body with yellow opaque cap. The capsule bears the inscription
?MONODOX 50? in brown and ?M 260? in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg
doxycycline.
MONODOX
?
50 mg is available in: Bottles of 100 capsul
es ...........
...............
...............
.............NDC
16110-260-06
Monodox
?
Doxycycline Monohydrate Capsules
Aqua Pharmaceuticals, LLC
Revised: January 2012
Rx only
191158-2
Page 13 of 14
MONODOX
?
75 mg Capsules have white opaque body with brown opaque cap. The capsule bears the inscription
"MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg
doxycycline.
MONODOX
?
75 mg is available in:
Bottles of 100 capsules .....
................
...............
...............
...NDC 16110-075-01
MONODOX
?
100 mg Capsules have yellow opaque body with brown opaque cap. The capsule bears the inscription
?MONODOX 100? in white and ?M 259? in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of
doxycycline.
MONODOX
?
100 mg is available in:
Bottles of 50 capsules .....
...............
...............
............
.........NDC
16110-259-04
Bottles of 250 capsules .....
................
...............
...............
...NDC 16110-259-07
STORE AT 20? 25?C (68? 77?F).
[SEE USP CONTROLLED ROOM TEMPERATURE.]
DISPENSE IN TIGHT LIGHT-RESISTANT
CONTAINER AS DEFINED IN THE USP/NF.
ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY
Hyperpigmentation of the thyroid has been produced by members of
the tetracycline class in the following species: in rats by
oxytetracycline, doxycycline, tetracycline PO
4
, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO
4
,
and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.
Minocycline, tetracycline PO
4
, methacycline, doxycyclin
e, tetracycline base, oxytetracyclin
e HCl and tetracycline HCl were
goitrogenic in rats fed low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake.
Administration of minocycline also produced large goiter with high radioiodine uptake in rats fed relatively high iodine di
et.
Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the
following: in rats and dogs (minocycline), in chickens (chlorte
tracycline) and in rats and mi
ce (oxytetracycline). Adrenal glan
d
hyperplasia has been observed in goats and rats treated with oxytetracycline.

NDC 00527-1338-50 UPC/GTIN No.3-05271-33850-1 Mfg.Part No.133850
RX ITEM-Doxycycline Mono 100Mg Tab 50 By
NDC 00527-1338-50 UPC/GTIN No.3-05271-33850-1 Mfg.Part No.133850

BRAND: DOXYCYCLINE NDC: 00527-1338-50,527133850 UPC: 3-05271-33850-1,305271338501 Lannett Co Inc
Lannett Co Inc
BRAND: DOXYCYCLINE NDC: 00527-1338-50,527133850 UPC: 3-05271-33850-1,305271338501 Lannett Co Inc

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
Click above for Vibramycin
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.